Streetbeat News

Analyst Ratings

TEX

Baird analyst Mircea Dobre maintains a Neutral rating on Terex (NYSE:TEX) and raises the price target from $57 to $65.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 12:46 pm

EYPT

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a price target of $27.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:46 pm

ACAD

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a price target of $33.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:46 pm

CGNX

Cognex (NASDAQ:CGNX) reported Q2 earnings of $0.32 per share, beating the analyst consensus estimate of $0.28 by 14.29%. However, this is a 21.95% decrease from the same period last year. The company also reported quarterly sales of $242.51 million, beating the analyst consensus estimate of $237.76 million by 2.00%, but this is a 11.69% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 12:46 pm

PCRX

HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $68 to $63.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:46 pm

APD

Air Products & Chemicals (NYSE:APD) has raised its FY2023 adjusted EPS guidance from $11.20-11.50 to $11.30-11.50, compared to the analyst estimate of $11.34. The company's 2022 adjusted diluted EPS was $10.41, excluding the per share impact of non-service pension benefit.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 12:46 pm

VCEL

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on Vericel (NASDAQ:VCEL) and raises the price target from $37 to $41.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:45 pm

GTHX

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on G1 Therapeutics (NASDAQ:GTHX) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:45 pm

KPTI

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:45 pm

GLYC

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on GlycoMimetics (NASDAQ:GLYC) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:45 pm